Consano Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica
Latest PR Newswire FDA coverage of Consano Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful L
Consano Bio
Private
Consano Bio is a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions. Recently received FDA IND clearance to expand its C-1101 chronic sciatica clinical development program into the United States.
Company Info
Upcoming Milestones & Key Dates
Q4 2026
Clinical
US clinical site activation
Clinical Development Pipeline
C-1101
Target: TBDUndisclosed
Target: TBDUndisclosed
Target: TBDRecent News
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer